Brief: Verastem Initiates Phase 2 Target-D 202 Trial For Advanced NSCLC
03/06/2026 21:06
BRIEF-Verastem Initiates Phase 2 Target-D 202 Trial For Advanced NSCLC June 3 (Reuters) - Verastem Inc VSTM.O:
VERASTEM ONCOLOGY ANNOUNCES U.S. FDA FAST TRACK DESIGNATION FOR VERSUS-7375, AN ORAL AND POTENTIAL BEST-IN-CLASS INVESTIGATIONAL KRAS G12D (ON/OFF) INHIBITOR FOR THE TREATMENT OF KRAS G12D-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
VERASTEM - INITIATES PHASE 2 TARGET-D 202 TRIAL FOR ADVANCED NSCLC
Source text: ID:nBw8Zw7mXa
Further company coverage: VSTM.O
((Reuters.Briefs@thomsonreuters.com;))